Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Clinical trial NCT04825990 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04825990
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-24
- Primary completion
- 2025-11-03
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.